Synapse - Works

Results (22057)

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development

Meeting Abstract

Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results

Meeting Abstract

Loriot, Y.; Schuler, M. H.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy

Meeting Abstract

Lebow, E. S.; Murciano-Goroff, Y. R.; Jee, J.; Kalashnikova, E.; Feeney, J.; Sethi, H.; Aleshin, A.; Kris, M. G.; Chaft, J. E.; Rudin, C. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer

Meeting Abstract

Landen, C. N.; Buckanovich, R. J.; Sill, M.; Mannel, R. S.; Walker, J. L.; Disilvestro, P.; Mathews, C. A.; Mutch, D. G.; Hernandez, M.; Martin, L. P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx)

Meeting Abstract

Le, X.; Paz-Ares, L.; Van Meerbeeck, J.; Ramirez, S. V.; Galvez, C. C.; Baz, D. V.; Kim, Y. C.; Kang, J. H.; Stroh, C.; Juraeva, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors

Meeting Abstract

Le, X.; Carneiro, B. A.; Hong, D. S.; Birnbaum, A. E.; Taylor, M. H.; Patel, S. A.; William, W. N.; Wang, B.; Beca, F.; Jain, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer

Meeting Abstract

Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion

Meeting Abstract

Lamoureux, A. A.; Fisher, M. J.; Lemelle, L.; Pfaff, E.; Pfister, S. M.; Sturm, D.; Jones, D. T. W.; Orbach, D.; Raskin, S.; Drilon, A. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody-drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)

Meeting Abstract

Lakhani, N. J.; Friedman, C. F.; Perez, C. A.; Wehr, A.; McGoldrick, S. M.; LoRusso, P.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer

Meeting Abstract

Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save